publication . Article . Other literature type . 2016

Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial

Zhu, Andrew X.; Kang, Yoon-Koo; Rosmorduc, Olivier; Evans, T.R. Jeffrey; Santoro, Armando; Ross, Paul; Gane, Edward; Vogel, Arndt; Jeffers, Michael; Meinhardt, Gerold; ...
  • Published: 24 May 2016
  • Country: India
Abstract
Purpose: Sorafenib is the current standard therapy for advanced hepatocellular carcinoma, but validated biomarkers predicting clinical outcomes are lacking. This study aimed to identify biomarkers predicting prognosis and/or response to sorafenib, with or without erlotinib, in hepatocellular carcinoma patients from the phase III SEARCH trial. Experimental Design: A total of 720 patients were randomized to receive oral sorafenib 400 mg twice daily plus erlotinib 150 mg once daily or placebo. Fifteen growth factors relevant to the treatment regimen and/or to hepatocellular carcinoma were measured in baseline plasma samples. Results: Baseline plasma biomarkers were...
Subjects
free text keywords: Pharmacology, Regimen, Oncology, medicine.medical_specialty, medicine, Internal medicine, Vascular endothelial growth factor C, Hepatocellular carcinoma, medicine.disease, Biomarker (medicine), business.industry, business, Cancer, Erlotinib, medicine.drug, Sorafenib, Cancer research, Placebo

2D3o9wnloaded from clincancerre2s9.aacrjournals.org on May 26, 28016. © 2016 American Assoc1iation for Cancer Research.

Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue